Targeted androgen pathway suppression in localized prostate cancer: A pilot study

Journal of Clinical Oncology

Volumn 32, Issue 3, 2014, Pages 229-237

  Mostaghel, Elahe A ^a,b   Nelson, Peter S ^b   Lange, Paul ^b   Lin, Daniel W ^b   Taplin, Mary Ellen ^d   Balk, Steven ^e   Ellis, William ^b   Kantoff, Philip ^d   Marck, Brett ^c   Tamae, Daniel ^f   Matsumoto, Alvin M ^c   True, Lawrence D ^c   Vessella, Robert ^b   Penning, Trevor ^f   Merrill, Rachel Hunter ^a   Gulati, Roman ^a   Montgomery, Bruce ^b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; ANDROSTERONE; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AZASTEROID; BICALUTAMIDE; CYP17A1 PROTEIN, HUMAN; DUTASTERIDE; GOSERELIN; KETOCONAZOLE; NITRILE; PROSTATE SPECIFIC ANTIGEN; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TOLUENESULFONIC ACID DERIVATIVE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; BLOOD; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PILOT STUDY; PROSTATE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VERY ELDERLY;

5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROSTERONE; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZASTEROIDS; CHEMOTHERAPY, ADJUVANT; DIHYDROTESTOSTERONE; GOSERELIN; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM STAGING; NITRILES; PILOT PROJECTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE; TOSYL COMPOUNDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84897018817     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.6431     Document Type: Article

References (32)

1. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003 (Pubitemid 36859473)
2. Andriole GL, Bostwick DG, Brawley OW, et al: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202, 2010
3. Forti G, Salerno R, Moneti G, et al: Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: Effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J Clin Endocrinol Metab 68:461-468, 1989 (Pubitemid 19052893)
4. Titus MA, Gregory CW, FordOH3rd, et al: Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11:4365-4371, 2005 (Pubitemid 40825625)
5. Page ST, Lin DW, Mostaghel EA, et al: Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91:3850-3856, 2006 (Pubitemid 44536854)
6. Mostaghel EA, Page ST, Lin DW, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041, 2007 (Pubitemid 46910214)
7. Gleave ME, La Bianca SE, Goldenberg SL, et al: Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 56:289-294, 2000 (Pubitemid 30495585)
8. Soloway MS, Pareek K, Sharifi R, et al: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112-116, 2002 (Pubitemid 34024512)
9. van der Kwast TH, Amin MB, Billis A, et al: International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens: Working group 2-T2 substaging and prostate cancer volume. Mod Pathol 24:16-25, 2011
10. Kalhorn TF, Page ST, Howald WN, et al: Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21:3200-3206, 2007 (Pubitemid 47441781)
11. Lucas JM, True L, Hawley S, et al: The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol 215:118-125, 2008 (Pubitemid 351786030)
12. Hothorn T, Bretz F, Westfall P: Simultaneous inference in general parametric models. Biom J 50:346-363, 2008
13. Hothorn T, Zeileis A: Generalized maximally selected statistics. Biometrics 64:1263-1269, 2008
14. Gleave ME, Goldenberg SL, Jones EC, et al: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155:213-219, 1996 (Pubitemid 126426468)
15. Stewart AJ, Scher HI, Chen MH, et al: Prostatespecific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005 (Pubitemid 46190248)
16. Mostaghel EA, Geng L, Holcomb I, et al: Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: Implications for prostate cancer chemoprevention. Cancer Res 70:1286-1295, 2010
17. Grino PB, Griffin JE, Wilson JD: Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126:1165-1172, 1990 (Pubitemid 20079537)
18. Gregory CW, Johnson RT Jr, Mohler JL, et al: Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898, 2001 (Pubitemid 32691931)
19. Carter HB, Sauvageot J, Walsh PC, et al: Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 157:2206-2209, 1997 (Pubitemid 27208672)
20. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007 (Pubitemid 350013847)
21. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003 (Pubitemid 37025405)
22. Rödel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688-8696, 2005 (Pubitemid 46211512)
23. Mostaghel EA, Marck BT, Plymate SR, et al: Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913-5925, 2011
24. Hu R, Lu C, Mostaghel EA, et al: Distinct transcriptional programs mediated by the liganddependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72:3457-3462, 2012
25. Guo Z, Yang X, Sun F, et al: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313, 2009
26. Thomas LN, Douglas RC, Lazier CB, et al: Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 179:147-151, 2008 (Pubitemid 350216746)
27. Montgomery RB, Mostaghel EA, Vessella R, et al: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454, 2008
28. Cai C, Chen S, Ng P, et al: Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71:6503-6513, 2011
29. Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586, 2011
30. Mulholland DJ, Tran LM, Li Y, et al: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804, 2011
31. Garraway LA, Sellers WR: Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6:593-602, 2006 (Pubitemid 44140858)
32. Nelson PS: Molecular states underlying androgen receptor activation: A framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 30:644-646, 2012